Response to Andrew Dunning's comment on 'evaluating a surrogate endpoint at three levels, with application to vaccine development'

Statistics in Medicine

Volumn 28, Issue 4, 2009, Pages 716-719

  Gilbert, Peter B ^a   Qin, Li ^a   Self, Steven G ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; INFLUENZA VACCINE; PLACEBO; VACCINE;

DRUG EFFICACY; IMMUNE RESPONSE; IMMUNOGENICITY; NOTE; QUANTITATIVE ANALYSIS; RANDOMIZATION; SENSITIVITY ANALYSIS; STATISTICAL ANALYSIS; VACCINE PRODUCTION; BIOMETRY; HUMAN; METHODOLOGY; RANDOMIZED CONTROLLED TRIAL; STATISTICAL MODEL;

BIOLOGICAL MARKERS; BIOMETRY; DATA INTERPRETATION, STATISTICAL; HUMANS; MODELS, STATISTICAL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VACCINES;

EID: 63149195123     PISSN: 02776715     EISSN: 10970258     Source Type: Journal    
DOI: 10.1002/sim.3503     Document Type: Note

References (5)

1. Sadoff JC, Wittes J. Correlates, surrogates, and vaccines. The Journal of Infectious Diseases 2007; 196:1279-1281.
2. Qin L, Gilbert PB, Corey L, McElrath J, Self SG. A framework for assessing immunological correlates of protection in vaccine trials. The Journal of Infectious Diseases 2007; 196:1304-1312.
3. Gilbert PB, Hudgens MG. Evaluating candidate principal surrogate endpoints. Biometrics 2008; DOI: 10.1111/ j.1541-0420.2008.01014.x.
4. Salk JE, Menke Jr WJ, Francis Jr T. A clinical, epidemiological and immunological evaluation of vaccination against epidemic influenza. American Journal of Hygiene 1943; 42:57-93.
5. Pearl J. Causality: Models, Reasoning, and Inference. Cambridge University Press: Cambridge, 2000.